Official Title Brief Digitally Enhanced Intervention for Managing Emotional Pain and Reducing Alcohol Use during Medication for OUD (Phase Two)

Purpose

This study is being done to further examine and improve how a brief clinical treatment intervention may reduce alcohol use among patients engaged in medication for opioid use disorder (MOUD) treatment.

The length of the study is approximately 10 weeks and will include two on-campus lab visits at Ohio State's Medical Campus, daily surveys via a smartphone app (surveys 3 times a day for ~21 days), three treatment sessions (completed online or in-person), and follow-up questionnaires (completed online). The total time commitment of the study is 11 hours and 6 minutes.

Could this study be right for you?

Inclusion Criteria:

• engaged in MOUD treatment (for at least one month)
• alcohol consumption (within the past 12 months)
• age 18 or older
• access to a smart phone

(partial list of inclusion criteria)

Exclusion Criteria:

• diagnosis of psychosis or bipolar I
• currently pregnant (positive pregnancy test)

(partial list of exclusion criteria)

Age Range

18 years and up

Official Title Depressive Episodes Associated with Bipolar I or II Disorder: A Double-Blind,
Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of
ABBV-932

Purpose

The purpose of this study is to see if the investigational study drug is safe and useful for treating patients with bipolar depression.

Eligible participants will be randomized to receive the drug or placebo. A placebo looks just like the investigational study drug but has no active drug in it.

The maximum duration of the study treatment period is 6 weeks. Participants receive psychiatric evaluation at each visit, and physical exam, urine test and blood draws at some of the visits. All study medication and procedures are provided at no cost, and participants may be compensated for their time and travel for each visit attended.

Could this study be right for you?

A diagnosis of bipolar disorder (type I or II) and be currently depressed.

Age Range

18 - 65 years

Official Title A Multicenter, Randomized, Double-Blind, Parallel-Group
Dose-Controlled Study Evaluating the Safety and Efficacy of
RE104 for Injection in the Treatment of Patients with
Postpartum Depression (PPD)

Purpose

The purpose of this study is to compare the effectiveness of two doses of an experimental medication, administered once, in reducing symptoms of depression in patients with postpartum depression.

 

Eligible participants will be assigned by chance to one of the two doses of the medication. The study includes 6 in-person visits and 4 telephone calls for up to 8 weeks.

Could this study be right for you?

To be eligible for this study, participants must meet the following criteria:

• Female aged 18 to 45 years
• Less than 12 months since delivery
• Currently depressed
• Not currently breastfeeding

Age Range

18 - 45 years

Official Title A Phase III, multicentre, randomised, double-blind,
controlled study to investigate the efficacy, safety,
and tolerability of two initial administrations of
COMP360 in participants with treatment-resistant
depression

Purpose

The study investigates a new approach for treatment-resistant depression using an investigational medicine related to psilocybin alongside psychological support.

Could this study be right for you?

You may be able to join the study if you:

—         Are 18 years of age or older

—         Have been diagnosed with major depression and have not responded to 2+ antidepressants

Other criteria will need to be met to confirm your eligibility for this study, which will last up to 62 weeks.

Age Range

18 years and up

Official Title A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the
Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of
Patients with Major Depressive Disorder

Purpose

Depression is one of the most common mental health issues worldwide. Many people with major depressive disorder (MDD) take antidepressant medications that do not provide enough of a response to ease their depressive symptoms.

The primary objective of this study is to evaluate the benefit of Lumateperone 42 mg administered once daily compared with placebo as adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) who have an inadequate response to ongoing ADT.

Could this study be right for you?

You may be able to take part if you:

• are 18–65 years of age

• have a confirmed diagnosis of Major Depressive Disorder (MDD)

• feel that your current antidepressant medication is not working well

• Has tried 2 or more antidepressant medication in the current episode of depression

 

Other criteria will need to be met to confirm your eligibility for this study.

Age Range

18 - 65 years

Official Title Developing Rumination-Focused Treatment to Reduce Risk for Depression Recurrence (RDR) in Adolescence (RuMeChange)

Purpose

We are conducting a study looking at how therapy strategies can help teenagers stay healthy, reduce rumination, or overthinking and worrying, and prevent depression relapse. If eligible, the teenager would complete assessments which include clinical interviews over Zoom, surveys, cognitive testing, and an MRI.

A parent/guardian is required to enroll in the study and will complete questionnaires and a clinical interview as well.

Could this study be right for you?

Inclusion Criteria:

• 14-17 years of age at enrollment
• Youth assent and parent consent

Exclusion Criteria:

• Metal braces, tattoos with metal
• Claustrophobia
• Current pregnancy

Age Range

14 - 17 years

Official Title An Examination of Culturally Responsive, Inclusive, and Socially Just Practices Parent Feedback

Purpose

The research study will examine parents’ - or a child’s primary caregiver - perspectives on an online professional development (PD) training for teachers, targeting early care and education (ECE) teachers’ use of culturally responsive, inclusive, and socially just practices. Parents of young children will be recruited to review the online PD course and complete surveys about the course. A subset of participants will participate in a focus group to share their feedback on the course.

Could this study be right for you?

Parent or caregiver to a child who:

• Is between 3 and 5 years old
• Is identified as Black/African American
• Attends a center-based early care and education program (pre-kindergarten, Head Start, child care, preschool, etc.)

Age Range

17 - 99 years

Official Title Progression of Social Cognitive Deficits in Mid- and Late-Life Schizophrenia Spectrum Disorders

Purpose

This research is being done to investigate the effects of age on social cognition in schizophrenia spectrum disorder. The study also hopes to examine potential neural bases of social cognition. The findings of the research will help develop effective treatment strategies by identifying who, when, and how to intervene.

Could this study be right for you?

Patients:

• Diagnosis of a schizophrenia spectrum disorder (includes schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, schizophreniform disorder, unspecified or other-specified psychotic disorders)

Healthy Controls:

• No history of any psychotic disorder
• No psychiatric diagnosis in the last 5 years
• Not taking psychotropic medication

 

Age Range

35 - 75 years

Official Title The mom and infant outcomes (MOMI) study: A trial of perinatal outpatient delivery systems

Purpose

​To improve our ability to provide the best possible care to every mom and infant, we are testing two different models of primary care during the first year after childbirth.

Could this study be right for you?

• You may qualify if you’re currently pregnant – AND – you’ve ever had high blood pressure, diabetes, depression, or anxiety, including during pregnancy.

If you participate, you’ll be randomly assigned to an Ohio State location that delivers one of two models of care. Providers at all locations can help you manage your health, but the models differ in several ways.

• You’ll complete three study visits with surveys, several measurements, and blood and hair sampling. We’ll collect cord blood and review medical records.

Official Title Examining the safety and clinical efficacy of psilocybin therapy for Veterans with PTSD: An open label proof-of-concept trial

Purpose

The study will demonstrate the safety and efficacy of psilocybin in treating post-traumatic stress disorder (PTSD) in veterans. Psilocybin-assisted therapy has shown great promise in treating anxiety symptoms that comprise post-traumatic stress disorder (PTSD).  Current therapeutic treatments for PTSD are difficult to tolerate and limited in efficacy, especially in the US military veteran population. This study will examine the safety and efficacy of two psilocybin sessions, combined with psychotherapy, among military veterans with severe, treatment resistant PTSD.

Could this study be right for you?

Inclusion criteria:

• Be a United States military veteran 
• 21 to 64 years old  
• Have at least a high-school level of education or equivalent (e.g. GED)
• Current diagnosis of PTSD
• Be medically stable as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG), and routine medical blood and urinalysis laboratory tests  

Exclusion criteria:  

• Women who are pregnant
• Cardiovascular conditions: coronary artery disease, stroke, angina, uncontrolled hypertension, a clinically significant ECG abnormality (e.g., atrial fibrillation), artificial heart valve, or TIA in the past year  
• High blood pressure
• History of seizures or epilepsy

Exclusion Criteria varies, please contact Study Coordinator.

 

Age Range

21 - 64 years